Navigation Links
OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
Date:7/29/2008

OREX-003 Being Developed as an Antipsychotic Agent with Less Potential for

Treatment-Associated Weight Gain and Metabolic Risks

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for a patent application that would provide broad coverage for a pharmaceutical composition of zonisamide in combination with a series of marketed atypical antipsychotics. Orexigen is currently evaluating a combination product, OREX-003, for the treatment of schizophrenia that it hopes would minimize the potential for weight gain or other adverse metabolic consequences often observed in patients receiving atypical antipsychotic medications.

OREX-003 combines a proprietary sustained release formulation of zonisamide plus olanzapine (marketed as Zyprexa(R)). Preclinical studies conducted by Orexigen demonstrated that the addition of zonisamide prevented weight gain and elevated blood glucose associated with olanzapine alone. Zonisamide appears to reverse the olanzapine effects on appetite pathways in the brain as well as directly on peripheral fat cells, resulting in mitigation of weight gain and elevated blood sugar associated with olanzapine treatment. OZ-101, the Company's Phase II proof of concept trial for OREX-003, is scheduled to begin in the third quarter this year.

"This patent represents another successful milestone for Orexigen. If OREX-003 retains the proven efficacy profile of olanzapine while mitigating possible safety concerns, then it will address a significant public health challenge," said Orexigen President and CEO Gary Tollefson, M.D., Ph.D. "Research has indicated that th
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
2. Cara Therapeutics Secures $12.3 Million in Series C Extension Financing
3. United Therapeutics to Announce Second Quarter 2008 Financial Results Before Market Open on Thursday, July 31, 2008
4. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
5. Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment
6. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
7. CV Therapeutics to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008
8. Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008
9. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
10. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
11. Organizational Changes at Silence Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... August 19, 2014 Robin Williams’ passing ... can take on an individual. Symptoms range from ... expression, problems swallowing and severe depression. Parkinson’s disease ... off of dopamine producing neurons of the brain. ... disease that slowly and progressively gets worse, they look ...
(Date:8/19/2014)... In November 2012, the European Union (EU) mandated use of ... new PSUR – responding to the increasing need to understand ... Adopted in many regions, the main objectives of the PBRER ... critical analysis of new or emerging information on the risks ... of the potential benefits of a drug; and , ...
(Date:8/18/2014)... Dallas, Texas (PRWEB) August 19, 2014 ... China Linalool Industry” is a professional and in-depth ... report provides basic Linalool information, including its ... well as industry overview. This research covers the ... well as global industry analysis covering macroeconomic environment ...
(Date:8/18/2014)... Aug. 18, 2014   Sterne, Kessler, Goldstein & ... Washington, DC , announced today that ... Review (IPR) with the U.S. Patent and Trademark ... of BioReference Laboratories, Inc. (Nasdaq: BRLI).  These IPR petitions ... by Myriad Genetics, Inc. These patents have been asserted ...
Breaking Biology Technology:As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3
... NEW YORK, Sept. 7 Richard Gabriel, Chief,Executive ... DNAG),( http://www.dnaprint.com ) will be featured in an ... to take place on September 10 at 11,a.m. ... http://www.wallst.net by 8 p.m.,EDT on September 10. ...
... Inc. (Nasdaq: HGSI ) announced today that its ... New York will be webcast,and may be accessed at ... A member of Human Genome Sciences, senior management ... September 11, 2007 at 4:00 pm,Eastern Time. Investors ...
... Appeared More Effective Than rituximab ... in a ... GEN) announced today that ofatumumab (HuMax-CD20(R)) appeared more,effective at inducing ... in a pre-clinical study. The CD20,antibodies were incubated with tumor ...
Cached Biology Technology:WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics 2Genmab Announces Encouraging Preclinical Data for ofatumumab 2
(Date:8/19/2014)... August 19, 2014A new ovoid structure discovered in the ... contains a variety of minerals, and shows evidence of ... melting of the permafrost and mixing of surface and ... range of analytical studies to determine the origin of ... how this ovoid formed, point to the most likely ...
(Date:8/19/2014)... analyzed concentrations of African dust transported to South ... spring. These research findings offer new insight on ... of African dust, including the climate change-induced human ... increased African dust emissions in the coming decades., ... School of Marine and Atmospheric Science and colleagues ...
(Date:8/19/2014)... This news release is available in French . ... Stand: balancing the BENEFITS and RISKS of physical activity ... a stand on the promotion of childhood physical activity ... Applied Physiology, Nutrition, and Metabolism ( APNM ... of knowledge in the area of risk of physical ...
Breaking Biology News(10 mins):Life on Mars? Implications of a newly discovered mineral-rich structure 2Study of African dust transport to South America reveals air quality impacts 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 3
... may trigger the development of schizophrenia and other bipolar ... Faculty of Biological Sciences (UK) has shown that the ... these disorders by affecting the production of dopamine - ... aspects of movement, cognition and behaviour. Toxoplasmosis, which ...
... in genes which can result in changes in the ... associated with susceptibility to common diseases. In a new ... the Association for Psychological Science, psychologist Tina B. Lonsdorf ... and the University of Greifswald in Germany examined the ...
... fluoride (SO 2 F 2 ), a gas commonly used to ... that remains in the atmosphere about 36 years, six to 10 ... by Jens Mhle, an atmospheric chemist at Scripps Institution of Oceanography, ... the gas rose at a rate of 4 to 6 percent ...
Cached Biology News:Research supports toxoplasmosis link to schizophrenia 2The genetics of fear: Study suggests specific genetic variations contribute to anxiety disorders 2Termite killer lingers as a potent greenhouse gas 2Termite killer lingers as a potent greenhouse gas 3
Normal human serum, single donor...
... Quality ISO 9001:2000 Certified ... All Precedures Validated, SOP's Training ... Process for All Procedures GLP Documentation Upon ... one stop shopping point for all your ...
Human IL-17D Affinity Purified Polyclonal Ab...
BBS/Glycerol/Casein Block and Diluent - 10X Concentrate, 1 L...
Biology Products: